Vinorelbine

Generic Name
Vinorelbine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C45H54N4O8
CAS Number
71486-22-1
Unique Ingredient Identifier
Q6C979R91Y
Background

Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .

It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting .

A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug .

Indication

Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .

Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .

For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .

For the treatment of recurrent or metastatic squamous cell head and neck cancer .

For the treatment of recurrent ovarian cancer .

For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .

For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .

Associated Conditions
Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
Associated Therapies
-

Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer

First Posted Date
2011-09-23
Last Posted Date
2011-09-23
Lead Sponsor
Shanghai CP Guojian Pharmaceutical Co., Ltd.
Target Recruit Count
109
Registration Number
NCT01439191
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

First Posted Date
2011-03-01
Last Posted Date
2018-12-17
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
32
Registration Number
NCT01305941
Locations
🇺🇸

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

🇺🇸

Carolinas Healthcare System, Charlotte, North Carolina, United States

🇺🇸

University Of Alabama at Birmingham, Birmingham, Alabama, United States

and more 1 locations

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

First Posted Date
2010-12-06
Last Posted Date
2012-01-25
Lead Sponsor
Incyte Corporation
Target Recruit Count
20
Registration Number
NCT01254136

Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer

Phase 2
Completed
Conditions
First Posted Date
2010-11-17
Last Posted Date
2015-05-21
Lead Sponsor
Vejle Hospital
Target Recruit Count
10
Registration Number
NCT01242449
Locations
🇩🇰

Dept. of Oncology, Aalborg Sygehus, Aalborg, Denmark

🇩🇰

Department of Oncology, Vejle Hospital, Vejle, Denmark

🇩🇰

Dept. of Oncology, Esbjerg Hospital, Esbjerg, Denmark

A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

First Posted Date
2010-09-08
Last Posted Date
2015-07-27
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
114
Registration Number
NCT01196078

Trastuzumab and Vinorelbine in Advanced Breast Cancer

First Posted Date
2010-08-20
Last Posted Date
2019-01-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
31
Registration Number
NCT01185509
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

First Posted Date
2010-05-18
Last Posted Date
2019-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
508
Registration Number
NCT01125566
Locations
🇦🇹

Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria

🇦🇷

Sanatorio Parque, Rosario, Argentina

🇺🇸

Ironwood Cancer and Research Centers, Chandler, Arizona, United States

and more 203 locations

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

First Posted Date
2010-04-23
Last Posted Date
2015-12-24
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
72
Registration Number
NCT01109524
Locations
🇺🇸

Cancer Care Institute, Los Angeles, California, United States

🇺🇸

Elite Research Institute, Miami, Florida, United States

🇺🇸

Mid Dakota Clinic, Pc, Bismarck, North Dakota, United States

and more 19 locations
© Copyright 2024. All Rights Reserved by MedPath